harmaline has been researched along with Benign Essential Tremor in 31 studies
Harmaline: A beta-carboline alkaloid isolated from seeds of PEGANUM.
harmaline : A harmala alkaloid in which the harman skeleton is methoxy-substituted at C-7 and has been reduced across the 3,4 bond.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Cerebellar EDCS suppressed harmaline tremor in rats in a polarity-dependent manner." | 8.31 | Epicranial Direct Current Stimulation Suppresses Harmaline Tremor in Rats. ( Asamoah, B; Boogers, A; Khatoun, A; Mc Laughlin, M, 2023) |
| "The results indicated that ABA (10 μg/rat) can improve harmaline-induced tremor in rats." | 8.12 | Phytohormone abscisic acid elicits positive effects on harmaline-induced cognitive and motor disturbances in a rat model of essential tremor. ( Naderi, R; Shabani, M, 2022) |
| "While harmaline has been used as a pharmacological model of essential tremor (ET) in rodents and pigs, less is known about the effects of this pharmacological treatment in awake-behaving non-human primates." | 8.02 | Considerations Using Harmaline for a Primate Model of Tremor. ( Bello, EM; Blumenfeld, M; Dao, J; Johnson, MD; Krieg, JDS; Wilmerding, LK, 2021) |
| "The primary cause of harmaline tremor, which is a model of essential tremor (ET) in animals, is excessive activation of olivocerebellar glutamatergic climbing fibers." | 7.96 | Inhibition of Excessive Glutamatergic Transmission in the Ventral Thalamic Nuclei by a Selective Adenosine A1 Receptor Agonist, 5'-Chloro-5'-Deoxy-(±)-ENBA Underlies its Tremorolytic Effect in the Harmaline-Induced Model of Essential Tremor. ( Berghauzen-Maciejewska, K; Konieczny, J; Kosmowska, B; Lenda, T; Ossowska, K; Wardas, J, 2020) |
| "The aim of the study was to examine the effects of preferential agonists of dopamine D3 receptors: pramipexole and 7-OH-DPAT on the harmaline-induced tremor in rats (a model of essential tremor, ET)." | 7.83 | Pramipexole at a Low Dose Induces Beneficial Effect in the Harmaline-induced Model of Essential Tremor in Rats. ( Ananthan, S; Głowacka, U; Kosmowska, B; Ossowska, K; Wardas, J, 2016) |
| "Recent work exploring the use of high-molecular weight alcohols to treat essential tremor (ET) has identified octanoic acid as a potential novel tremor-suppressing agent." | 7.78 | Octanoic acid suppresses harmaline-induced tremor in mouse model of essential tremor. ( Brown, T; Dong, C; Hallett, M; Handforth, A; Haubenberger, D; Nahab, FB; Quesada, A; Shin, C, 2012) |
| " We compared the two compounds for behavioral toxicity, effects on cytochrome P450 activity, and efficacy against tremor in the γ-aminobutyric acid type A (GABAA) receptor subunit α1-null mouse, and the harmaline tremor model of essential tremor in wild-type mice." | 7.77 | Comparison of mibefradil and derivative NNC 55-0396 effects on behavior, cytochrome P450 activity, and tremor in mouse models of essential tremor. ( Bui, PH; Handforth, A; Hankinson, O; Homanics, GE; Quesada, A, 2011) |
| "Recent experimental and clinical studies clearly suggest the role of gamma-aminobutyric acid (GABA) in the pathogenesis of tremors." | 7.71 | Baclofen attenuates harmaline induced tremors in rats. ( Al Deeb, S; Al Moutaery, K; Arshaduddin, M; Biary, N; Tariq, M, 2001) |
| "Pretreatment with agmatine reduced the percent tremor duration and intensity of tremor induced by harmaline, without affecting the tremor frequency." | 5.62 | Agmatine has beneficial effect on harmaline-induced essential tremor in rat. ( Akman, Ö; Arıcıoğlu, F; Ateş, N; Güllü, K; Karson, A; Utkan, T, 2021) |
| "Cerebellar EDCS suppressed harmaline tremor in rats in a polarity-dependent manner." | 4.31 | Epicranial Direct Current Stimulation Suppresses Harmaline Tremor in Rats. ( Asamoah, B; Boogers, A; Khatoun, A; Mc Laughlin, M, 2023) |
| " Only non-impairing doses were used to evaluate for anti-tremor efficacy in the harmaline model, which was assessed in wildtype and α6 subunit knockout littermates." | 4.31 | Search for Novel Therapies for Essential Tremor Based on Positive Modulation of α6-Containing GABA ( Ernst, M; Handforth, A; Singh, RP; Treven, M, 2023) |
| "The results indicated that ABA (10 μg/rat) can improve harmaline-induced tremor in rats." | 4.12 | Phytohormone abscisic acid elicits positive effects on harmaline-induced cognitive and motor disturbances in a rat model of essential tremor. ( Naderi, R; Shabani, M, 2022) |
| "While harmaline has been used as a pharmacological model of essential tremor (ET) in rodents and pigs, less is known about the effects of this pharmacological treatment in awake-behaving non-human primates." | 4.02 | Considerations Using Harmaline for a Primate Model of Tremor. ( Bello, EM; Blumenfeld, M; Dao, J; Johnson, MD; Krieg, JDS; Wilmerding, LK, 2021) |
| "Using this system, we were able to characterize both the microtremors in netrin-G2 KO mice and low-dose harmaline-induced tremors which, to date, had been difficult to detect." | 4.02 | Objective detection of microtremors in netrin-G2 knockout mice. ( Ajima, A; Itohara, S; Yaguchi, K; Yoshida, T, 2021) |
| "The primary cause of harmaline tremor, which is a model of essential tremor (ET) in animals, is excessive activation of olivocerebellar glutamatergic climbing fibers." | 3.96 | Inhibition of Excessive Glutamatergic Transmission in the Ventral Thalamic Nuclei by a Selective Adenosine A1 Receptor Agonist, 5'-Chloro-5'-Deoxy-(±)-ENBA Underlies its Tremorolytic Effect in the Harmaline-Induced Model of Essential Tremor. ( Berghauzen-Maciejewska, K; Konieczny, J; Kosmowska, B; Lenda, T; Ossowska, K; Wardas, J, 2020) |
| "The aim of the study was to examine the effects of preferential agonists of dopamine D3 receptors: pramipexole and 7-OH-DPAT on the harmaline-induced tremor in rats (a model of essential tremor, ET)." | 3.83 | Pramipexole at a Low Dose Induces Beneficial Effect in the Harmaline-induced Model of Essential Tremor in Rats. ( Ananthan, S; Głowacka, U; Kosmowska, B; Ossowska, K; Wardas, J, 2016) |
| "Recent work exploring the use of high-molecular weight alcohols to treat essential tremor (ET) has identified octanoic acid as a potential novel tremor-suppressing agent." | 3.78 | Octanoic acid suppresses harmaline-induced tremor in mouse model of essential tremor. ( Brown, T; Dong, C; Hallett, M; Handforth, A; Haubenberger, D; Nahab, FB; Quesada, A; Shin, C, 2012) |
| " We compared the two compounds for behavioral toxicity, effects on cytochrome P450 activity, and efficacy against tremor in the γ-aminobutyric acid type A (GABAA) receptor subunit α1-null mouse, and the harmaline tremor model of essential tremor in wild-type mice." | 3.77 | Comparison of mibefradil and derivative NNC 55-0396 effects on behavior, cytochrome P450 activity, and tremor in mouse models of essential tremor. ( Bui, PH; Handforth, A; Hankinson, O; Homanics, GE; Quesada, A, 2011) |
| "3 to 30 mg/kg), a new anticonvulsant drug, in a model of essential tremor in comparison to the reference compounds propranolol and primidone." | 3.74 | Lacosamide, the new anticonvulsant, effectively reduces harmaline-induced tremors in rats. ( Freitag, J; Lekieffre, D; Stöhr, T, 2008) |
| "Recent experimental and clinical studies clearly suggest the role of gamma-aminobutyric acid (GABA) in the pathogenesis of tremors." | 3.71 | Baclofen attenuates harmaline induced tremors in rats. ( Al Deeb, S; Al Moutaery, K; Arshaduddin, M; Biary, N; Tariq, M, 2001) |
| "Harmaline-induced tremor is an easily provoked model for the development of new therapies for essential tremor (ET)." | 1.91 | Mapping Pharmacologically Evoked Neurovascular Activation and Its Suppression in a Rat Model of Tremor Using Functional Ultrasound: A Feasibility Study. ( Alizad, A; Chang, SY; Fatemi, M; Lee, J; Nayak, R; Sotoudehnia, S, 2023) |
| "Pretreatment with agmatine reduced the percent tremor duration and intensity of tremor induced by harmaline, without affecting the tremor frequency." | 1.62 | Agmatine has beneficial effect on harmaline-induced essential tremor in rat. ( Akman, Ö; Arıcıoğlu, F; Ateş, N; Güllü, K; Karson, A; Utkan, T, 2021) |
| "Essential tremor is a common disorder that lacks molecular targets for therapeutic development." | 1.36 | T-type calcium channel antagonists suppress tremor in two mouse models of essential tremor. ( Covey, DF; Handforth, A; Homanics, GE; Krishnan, K; Lee, JY; Martin, FC; Quesada, A; Sakimura, K, 2010) |
| "Essential tremor is one of the most common movement disorders in elderly people." | 1.35 | A possible mechanism for the beneficial effect of ethanol in essential tremor. ( Laute, MA; Manto, M, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (16.13) | 29.6817 |
| 2010's | 13 (41.94) | 24.3611 |
| 2020's | 13 (41.94) | 2.80 |
| Authors | Studies |
|---|---|
| Bello, EM | 1 |
| Blumenfeld, M | 1 |
| Dao, J | 1 |
| Krieg, JDS | 1 |
| Wilmerding, LK | 1 |
| Johnson, MD | 1 |
| Shabani, M | 7 |
| Naderi, R | 1 |
| Lee, J | 2 |
| Kim, J | 1 |
| Cortez, J | 1 |
| Chang, SY | 2 |
| Khatoun, A | 1 |
| Asamoah, B | 1 |
| Boogers, A | 1 |
| Mc Laughlin, M | 1 |
| Kuo, SH | 1 |
| Kosmowska, B | 3 |
| Paleczna, M | 1 |
| Biała, D | 1 |
| Kadłuczka, J | 1 |
| Wardas, J | 3 |
| Witkin, JM | 1 |
| Cook, JM | 1 |
| Sharmin, D | 1 |
| Marcinkowska, M | 1 |
| Kuter, KZ | 1 |
| Handforth, A | 7 |
| Kosoyan, HP | 1 |
| Kadam, PA | 1 |
| Singh, RP | 2 |
| Nayak, R | 1 |
| Sotoudehnia, S | 1 |
| Fatemi, M | 1 |
| Alizad, A | 1 |
| Treven, M | 1 |
| Ernst, M | 1 |
| Ossowska, K | 2 |
| Konieczny, J | 1 |
| Lenda, T | 1 |
| Berghauzen-Maciejewska, K | 1 |
| Ajima, A | 1 |
| Yoshida, T | 1 |
| Yaguchi, K | 1 |
| Itohara, S | 1 |
| Akman, Ö | 1 |
| Utkan, T | 1 |
| Arıcıoğlu, F | 1 |
| Güllü, K | 1 |
| Ateş, N | 1 |
| Karson, A | 1 |
| Dahmardeh, N | 1 |
| Asadi-Shekaari, M | 1 |
| Arjmand, S | 1 |
| Kalantaripour, T | 1 |
| Basiri, M | 1 |
| Jiménez-Jiménez, FJ | 1 |
| Alonso-Navarro, H | 1 |
| García-Martín, E | 1 |
| Agúndez, JAG | 1 |
| Aghaei, I | 3 |
| Hajali, V | 1 |
| Haghani, M | 2 |
| Vaziri, Z | 3 |
| Moosazadeh, M | 1 |
| Mohammadi, F | 1 |
| Abedini Esfahlani, M | 1 |
| Carlsen, EMM | 1 |
| Amrutkar, DV | 1 |
| Sandager-Nielsen, K | 1 |
| Perrier, JF | 1 |
| Vilela-Filho, O | 1 |
| Ferraz, FP | 1 |
| Barros, BA | 1 |
| Silva, LO | 1 |
| Anunciação, SF | 1 |
| Souza, JT | 1 |
| Silva, DJ | 1 |
| Leite, MB | 1 |
| Atayde, IB | 1 |
| Ragazzo, PC | 1 |
| Barreto, PG | 1 |
| Nobrega, MA | 1 |
| Araujo, MR | 1 |
| Santos, MR | 1 |
| Ala, VH | 1 |
| Queiroz, ST | 1 |
| Louis, ED | 1 |
| Abbassian, H | 3 |
| Sheibani, V | 3 |
| Nazeri, M | 1 |
| Głowacka, U | 1 |
| Ananthan, S | 1 |
| Esmaeili, P | 1 |
| Tahamtan, M | 1 |
| Whalley, BJ | 2 |
| Stöhr, T | 1 |
| Lekieffre, D | 1 |
| Freitag, J | 1 |
| Homanics, GE | 2 |
| Covey, DF | 1 |
| Krishnan, K | 1 |
| Lee, JY | 1 |
| Sakimura, K | 1 |
| Martin, FC | 3 |
| Quesada, A | 3 |
| Bui, PH | 1 |
| Hankinson, O | 1 |
| Nahab, FB | 1 |
| Brown, T | 1 |
| Shin, C | 1 |
| Dong, C | 1 |
| Haubenberger, D | 1 |
| Hallett, M | 1 |
| Thu Le, A | 1 |
| Manto, M | 1 |
| Laute, MA | 1 |
| Tariq, M | 1 |
| Arshaduddin, M | 1 |
| Biary, N | 1 |
| Al Moutaery, K | 1 |
| Al Deeb, S | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| a Pilot Study of Pramipexole to Treat Extrapyramidal Symptoms Induced by Antipsychotics[NCT03430596] | Early Phase 1 | 50 participants (Actual) | Interventional | 2018-05-01 | Completed | ||
| Effects of Octanoic Acid for Treatment of Essential Voice Tremor[NCT01864525] | Phase 1/Phase 2 | 17 participants (Actual) | Interventional | 2013-07-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Three experienced listeners independently rated each participant's voice from paired sample recordings comparing the baseline to post-test samples in randomized order for each condition. Sustained vowel and sentence-level recordings were rated, with decoded samples later analyzed for 1=better for post-test compared to baseline, 0= no difference between post-test and baseline. Maximum score for each participant was 3 (post-test was better for each of three raters). The range of possible scores was the sum of each of three raters' scores (0 to 3), with 0 indicating no difference between baseline and post-test voice tremor severity rating, and 3 indicating better voice (less tremor severity) at post-testing compared to pre-testing. Mean post-test values for task were compared for the octanoic acid and placebo conditions, and all raters were blind to which sample was a baseline versus a post-test recording, and which samples were associated with the [placebo or octanoic acid conditions. (NCT01864525)
Timeframe: Measured at baseline visits (1 & 2) and after 3 weeks of placebo or octanoic acid on post-test visits (1 & 2).
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Sustained vowel, summed binary ratings (0-3) | Sentence-level, summed binary ratings (0-3) | |
| Octanoic Acid | 1.53 | 1.19 |
| Placebo | 1.25 | 1.63 |
Voice recordings were used to measure the degree of tremor in the voice. Mean post-test values for each acoustic measure were compared after the octanoic acid and placebo conditions, with and without consideration of baseline values. Mean values represent the average of two testing days. Degree of amplitude tremor shows the extent of amplitude variation as a percent of the mean signal amplitude, with lower numbers indicating less amplitude tremor. Baseline values for magnitude of amplitude tremor across all participants and conditions ranged from 4.06 to 27.09, and post-test values ranged from 1.94 to 26.02. Degree of frequency tremor shows the extent of fundamental frequency variation as a percent of the mean signal frequency, with lower numbers indicating less frequency tremor. Baseline values for magnitude of frequency tremor across all participants and conditions ranged from 1.21 to 15.31, and post-test values ranged from 0.60 to 13.86. (NCT01864525)
Timeframe: Measured at baseline visits (1 & 2) and after 3 weeks of placebo or octanoic acid on post-test visits (1 & 2)
| Intervention | percentage of voice signal with tremor (Mean) | |||
|---|---|---|---|---|
| Baseline Magnitude of Acoustic Amplitude Tremor | Post-test Magnitude of Acoustic Amplitude Tremor | Baseline Magnitude of Acoustic Frequency Tremor | Post-test Magnitude of Acoustic Frequency Tremor | |
| Octanoic Acid | 13.49 | 9.35 | 5.19 | 3.98 |
| Placebo | 12.91 | 12.43 | 5.57 | 5.35 |
2 reviews available for harmaline and Benign Essential Tremor
| Article | Year |
|---|---|
An Update on the Neurochemistry of Essential Tremor.
Topics: Dopamine; Essential Tremor; Harmaline; Humans; Neurochemistry; Neurotransmitter Agents | 2020 |
Re-thinking the biology of essential tremor: from models to morphology.
Topics: Animals; Central Nervous System Stimulants; Essential Tremor; Harmaline; Humans; Models, Biological; | 2014 |
29 other studies available for harmaline and Benign Essential Tremor
| Article | Year |
|---|---|
Considerations Using Harmaline for a Primate Model of Tremor.
Topics: Animals; Essential Tremor; Harmaline; Humans; Macaca mulatta; Swine; Tremor | 2021 |
Phytohormone abscisic acid elicits positive effects on harmaline-induced cognitive and motor disturbances in a rat model of essential tremor.
Topics: Abscisic Acid; Animals; Cognition; Essential Tremor; Harmaline; Male; Mammals; Neuroprotective Agent | 2022 |
Thalamo-cortical network is associated with harmaline-induced tremor in rodent model.
Topics: Animals; Deep Brain Stimulation; Essential Tremor; Harmaline; Motor Cortex; Propranolol; Rats; Roden | 2022 |
Epicranial Direct Current Stimulation Suppresses Harmaline Tremor in Rats.
Topics: Animals; Cerebellum; Essential Tremor; Harmaline; Rats; Rats, Sprague-Dawley; Tremor | 2023 |
GABA
Topics: Cerebellum; Essential Tremor; Harmaline; Humans; Receptors, GABA-A; Tremor | 2023 |
GABA-A Alpha 2/3 but Not Alpha 1 Receptor Subunit Ligand Inhibits Harmaline and Pimozide-Induced Tremor in Rats.
Topics: Animals; Essential Tremor; gamma-Aminobutyric Acid; Harmaline; Ligands; Pimozide; Rats; Rats, Spragu | 2023 |
Alcohol and Ganaxolone Suppress Tremor via Extra-Synaptic GABA
Topics: Animals; Essential Tremor; Ethanol; gamma-Aminobutyric Acid; Harmaline; Humans; Mice; Receptors, GAB | 2023 |
Mapping Pharmacologically Evoked Neurovascular Activation and Its Suppression in a Rat Model of Tremor Using Functional Ultrasound: A Feasibility Study.
Topics: Animals; Essential Tremor; Feasibility Studies; Harmaline; Propranolol; Rats; Tremor | 2023 |
Search for Novel Therapies for Essential Tremor Based on Positive Modulation of α6-Containing GABA
Topics: Animals; Essential Tremor; Flumazenil; gamma-Aminobutyric Acid; Harmaline; Humans; Ketamine; Mice; M | 2023 |
Inhibition of Excessive Glutamatergic Transmission in the Ventral Thalamic Nuclei by a Selective Adenosine A1 Receptor Agonist, 5'-Chloro-5'-Deoxy-(±)-ENBA Underlies its Tremorolytic Effect in the Harmaline-Induced Model of Essential Tremor.
Topics: Adenosine A1 Receptor Agonists; Animals; Essential Tremor; Harmaline; Rats; Rats, Wistar; Ventral Th | 2020 |
Objective detection of microtremors in netrin-G2 knockout mice.
Topics: Animals; Essential Tremor; Harmaline; Humans; Mice; Mice, Knockout; Netrins; Tremor | 2021 |
Agmatine has beneficial effect on harmaline-induced essential tremor in rat.
Topics: Agmatine; Animals; Central Nervous System Stimulants; Disease Models, Animal; Essential Tremor; Harm | 2021 |
Modulation of sphingosine-1-phosphate receptor ameliorates harmaline-induced essential tremor in rat.
Topics: Animals; Anxiety; Behavior, Animal; Central Nervous System Stimulants; Disease Models, Animal; Essen | 2017 |
Peroxisome proliferator-activated receptor-γ activation attenuates harmaline-induced cognitive impairments in rats.
Topics: Animals; Behavior, Animal; Cognitive Dysfunction; Essential Tremor; Harmaline; Male; Maze Learning; | 2019 |
Erythropoietin ameliorates harmaline-induced essential tremor and cognition disturbances.
Topics: Animals; Anxiety; Biomechanical Phenomena; Cognition Disorders; Erythropoietin; Essential Tremor; Ex | 2019 |
Accurate and affordable assessment of physiological and pathological tremor in rodents using the accelerometer of a smartphone.
Topics: Accelerometry; Animals; Central Nervous System Stimulants; Disease Models, Animal; Essential Tremor; | 2019 |
Effects of unilateral stereotactic posterior striatotomy on harmaline-induced tremor in rats.
Topics: Animals; Central Nervous System Stimulants; Corpus Striatum; Disease Models, Animal; Essential Tremo | 2013 |
The therapeutic potential of Berberine chloride hydrate against harmaline-induced motor impairments in a rat model of tremor.
Topics: Animals; Anxiety; Berberine; Essential Tremor; Exploratory Behavior; Gait; Harmaline; Male; Motor Sk | 2015 |
Pramipexole at a Low Dose Induces Beneficial Effect in the Harmaline-induced Model of Essential Tremor in Rats.
Topics: Amisulpride; Animals; Anti-Dyskinesia Agents; Benzothiazoles; Disease Models, Animal; Dopamine Agoni | 2016 |
Cannabinoid receptor agonism suppresses tremor, cognition disturbances and anxiety-like behaviors in a rat model of essential tremor.
Topics: Animals; Anti-Anxiety Agents; Anti-Dyskinesia Agents; Anxiety; Avoidance Learning; Benzoxazines; Can | 2016 |
Cannabinoid type 1 receptor antagonism ameliorates harmaline-induced essential tremor in rat.
Topics: Animals; Cannabinoid Receptor Antagonists; Essential Tremor; Harmaline; Male; Rats; Rats, Wistar; Re | 2016 |
Lacosamide, the new anticonvulsant, effectively reduces harmaline-induced tremors in rats.
Topics: Acetamides; Animals; Anticonvulsants; Disease Models, Animal; Dose-Response Relationship, Drug; Esse | 2008 |
T-type calcium channel antagonists suppress tremor in two mouse models of essential tremor.
Topics: Analysis of Variance; Animals; Benzimidazoles; Calcium Channel Blockers; Calcium Channels, T-Type; C | 2010 |
Comparison of mibefradil and derivative NNC 55-0396 effects on behavior, cytochrome P450 activity, and tremor in mouse models of essential tremor.
Topics: Animals; Behavior, Animal; Benzimidazoles; Cyclopropanes; Cytochrome P-450 Enzyme System; Disease Mo | 2011 |
Octanoic acid suppresses harmaline-induced tremor in mouse model of essential tremor.
Topics: Animals; Caprylates; Central Nervous System Stimulants; Disease Models, Animal; Dose-Response Relati | 2012 |
Harmaline-induced tremor as a potential preclinical screening method for essential tremor medications.
Topics: Animals; Central Nervous System Depressants; Central Nervous System Stimulants; Essential Tremor; Et | 2005 |
Carbenoxolone and mefloquine suppress tremor in the harmaline mouse model of essential tremor.
Topics: 1-Octanol; Animals; Carbenoxolone; Central Nervous System Stimulants; Cerebellum; Chloroquine; Conne | 2006 |
A possible mechanism for the beneficial effect of ethanol in essential tremor.
Topics: Animals; Brain; Central Nervous System Depressants; Central Nervous System Stimulants; Essential Tre | 2008 |
Baclofen attenuates harmaline induced tremors in rats.
Topics: Animals; Baclofen; Brain; Dose-Response Relationship, Drug; Drug Interactions; Electromyography; Ess | 2001 |